InFarmatik recently joined a Cardiovascular MMP Consortium to serve as chemistry engine of the drug discovery project. The information you can find at

View the new compounds

InFarmatik News Letter Nov-Dec 2008


InFarmatik recently appointed Dénes Kónya, PhD, to the position of Director of Chemistry. Dr. Kónya whose last position was with AMRI Hungary as their Site Manager and Synthesis Group Leader, has extensive experience in combichem library synthesis and custom chemistry project/FTE management.

Michael Bossert was recently promoted to the position of Sales Director for Europe, Asia & Pacific. InFarmatik is exploring a partnership with Development Chemicals Ltd, a UK/US-based process development company that collaborates with production companies in Asia to provide low cost manufacturing solutions.

InFarmatik has expanded our drug discovery research services by forming strategic alliances with related and complementary drug discovery service providers Targetex Biosciences, a Hungarian protein expression and HT screening company and PharmaHungary, a preclinical and clinical pharmacology service provider. (The collaboration is based on InFarmatik’s successful MMP inhibitor consortium model. For further details, see www.mmpharma.com).

InFarmatik has released 39 novel products (building blocks, biologically active substances and their intermediates)